Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
Teva Pharmaceuticals の市場拡大を追跡しています
過去 90 日間に 66 件のシグナル。
Teva Pharmaceuticals の海外展開を競合と比較
Teva Pharmaceuticals自社バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
 Teva Pharmaceuticals自社 | 0 | 0 | — | 0 | 0 |
Quality Control Analyst I
求人を見るKfar Saba, Center District, Israel · 一昨日
Sr Director Supply Chain
求人を見るDupnitsa, Kyustendil, Bulgaria · 3日前
Manager, Category Excellence / Capability Lead ExM GP
求人を見るSofia, Sofia City, Bulgaria · 3日前
Today, we announced Teva Pharmaceuticals’ Q1 2026 financial results, marking a strong start to the year and reinforcing our transformation into a leading biopharma company.Our key innovative products are becoming an engine of sustainable growth, collectively growing 41% year-over-year in local currency and continuing to shift Teva’s portfolio mix. We also saw continued progress on our late-stage innovative pipeline and stable generics performance driven by biosimilars growth. That's what our Piv ...
実施中
Explore open roles at Teva India >>
実施中
This post is directed to HCPs only.Looking for expert perspectives on the evolving role of long-acting injectables (LAIs) in improving the lives of people living with schizophrenia?Come along to the Forum Hall at 13.15 on Sunday 29th March during EPA 2026 in Prague to hear from an expert faculty as they consider the evolving evidence, opinion and guidelines supporting the wider integration of LAIs into clinical practice.13.15-14.15, Forum Hall (second floor)https://lnkd.in/eqRnEUpf Please do n ...
終了テルアビブ証券取引所は上昇。タワーセミコンダクターとテバが上昇を主導。ベンク・レウミは高取引量で下落。
テバ製薬は3年連続の成長後、2026年の収益と利益の減少を予測し、予想収益は164-168億ドル、EPSは2.55-2.65ドルとなる見込み。
Teva製薬のAPI部門は、運営調整の一環として2年間でイスラエルで250人の雇用を削減し、主にベエルシェバ近郊のNeot Hovav工場に影響を与える。
認証済みメールと直通電話を解放
無料 · カード不要
Teva Pharmaceuticals の事業、市場、成長シグナルに関する簡潔な回答。
© 2026 Pubrio. 無断転載を禁じます。
